Ask AI
Back Back
Treatment Recommendations for MCL
Treatment Decision Support for Evolving MCL Treatment Paradigms

Released: May 26, 2026

Kami Maddocks
Kami Maddocks, MD
Activity Information

Activity

Continue to Activity
Key Takeaways
  • Decera Clinical Education’s interactive treatment decision support tool, developed by 5 experts in mantle cell lymphoma, provides expert guidance for healthcare professionals in an increasingly complex treatment landscape.

The treatment paradigm for mantle cell lymphoma (MCL) has rapidly evolved in the last decade, particularly in the last few years, driven by a deeper understanding of disease biology and the development of targeted therapies, including covalent BTK inhibitor–based regimens that include acalabrutinib and zanubrutinib, the noncovalent BTK inhibitor pirtobrutinib, and CAR T-cell therapies. In 2026, 5 experts in MCL developed an interactive treatment decision support tool to guide healthcare professionals in managing their patients’ treatment by incorporating key clinical and biologic variables into a structured framework.

Key Clinical Considerations in MCL Management
Key clinical considerations in the management of MCL include disease burden, patient fitness, and underlying biological risk factors. For asymptomatic patients with low-risk disease, a “watch-and-wait” approach may be appropriate, whereas symptomatic patients generally require prompt initiation of therapy. Given that many patients with MCL are older and have significant comorbidities, treatment selection must account for overall health status and the ability to tolerate aggressive therapies. Cytogenetic abnormalities, particularly TP53 mutation and del(17p), are associated with poor outcomes and may warrant consideration of alternative or investigational treatment strategies. Additional genetic features, including complex karyotype or c-MYC abnormalities, can help predict prognosis, even though they currently do not inform treatment selection. Finally, healthcare professionals must balance efficacy with safety by considering treatment-related toxicities, such as bleeding risk and cytopenias associated with BTK inhibitors and other targeted agents, when developing individualized treatment plans.

Decera Clinical Education, in collaboration with Brad Kahl, MD; Tycel J. Phillips, MD; Javier Munoz, MD, MS, MBA, FACP; Julie M. Vose, MD, MBA, and myself, has created an interactive online treatment decision support tool focused on MCL treatment. As a user of the tool, you can enter key patient and disease characteristics to define a patient scenario; these include TP53 mutation status, cytogenetic abnormalities, Ki-67 proliferation index, prior therapies, and comorbidities. After entering key patient and disease characteristics, you will select your intended treatment choice. After selecting your choice of therapy, the recommendations from all 5 experts for your individual set of characteristics will appear along with a link to additional information to consider.

Impact of Emerging Data and Targeted Therapies
BTK inhibitors such as acalabrutinib and zanubrutinib have become central to second-line therapy, and BTK inhibitor–based combination strategies are now increasingly being incorporated into the frontline setting. For example, for a patient with newly diagnosed symptomatic stage II-IV MCL without del(17p) or a TP53 ;mutation, complex cytogenetics, or Ki-67 ≥50%, 1 expert would recommend R-CHOP plus a covalent BTK inhibitor/R-DHAP (TRIANGLE), 3 experts would recommend acalabrutinib plus bendamustine plus rituximab (ECHO) (1 would also consider a covalent BTK inhibitor plus obinutuzumab plus venetoclax [BOVen, Oasis, MAVO]), and 1 would recommend a bendamustine/rituximab-based regimen.

Let’s look at another case from our tool, this one a younger patient with newly diagnosed advanced stage MCL with a TP53 mutation and normal karyotype, with a Ki-67 of 40%. For this case, all 5 experts would consider a BOVen regimen (zanubrutinib plus obinutuzumab plus venetoclax), with 2 experts also indicating that they would consider a MAVO regimen (acalabrutinib plus obinutuzumab plus venetoclax).

In addition, newer agents, such as the noncovalent BTK inhibitor pirtobrutinib, which received FDA accelerated approval for patients with relapsed/refractory MCL after ≥2 lines of systemic treatment including a BTK inhibitor, have expanded treatment options for patients with relapsed/refractory disease. Looking at a case from our tool, for an older, less fit patient who received frontline therapy with covalent BTK inhibitor–based therapy followed by covalent BTK inhibitor-based maintenance and experienced disease relapse after >1 year, 2 experts would recommend pirtobrutinib, 2 experts would recommend lisocabtagene maraleucel (CAR T-cell therapy), and 1 would recommend a covalent BTK inhibitor.

High-risk genetic features like those noted above remain a major challenge in MCL management. Although these abnormalities have been associated with poor outcomes following intensive chemoimmunotherapy and transplantation, emerging combination strategies are showing promise. Clinical trial participation is strongly encouraged for this patient subgroup.

Looking Ahead
Use of the interactive treatment decision support tool for MCL has demonstrated that incorporating patient-specific clinical variables and expert-driven recommendations can meaningfully influence healthcare professionals’ treatment choices and align them more closely with evolving evidence-based practices in both frontline and relapsed/refractory settings. As the therapeutic landscape of MCL continues to evolve, we anticipate regularly updating this platform to incorporate emerging clinical trial data, novel agents, and evolving guideline recommendations. Ultimately, our goal is to provide healthcare professionals with a practical, evidence-informed resource that enhances decision-making while acknowledging the complexity and individuality of each patient with MCL.

Your Thoughts
What resources do you use when making treatment decisions for patients with MCL? Have you used a treatment decision support tool when considering therapy for your patients? Try our latest tool for MCL treatment at deceraclinical.com/MCLTool. Let us know what you think with a comment in the discussion section below.

Continue to Activity

Poll

1.

How would you rate your knowledge of the expanding landscape of initial therapy options for MCL?

Submit